Skip to Content

Nyxoah, ResMed partner in Germany to accelerate sleep therapy 

Nyxoah, ResMed partner in Germany to accelerate sleep therapy 

MOUNT SAINT GUIBERT, Belgium – Nyxoah, a med tech company focused on the development and commercialization of innovative solutions to treat obstructive sleep apnea, has announced a partnership with ResMed Germany to increase awareness and therapy penetration in the German market. 

The companies will establish a continuum of care that will educate and guide OSA patients in the German market from diagnosis through treatment. 

"It is our joint goal to enable more patients to receive effective, personalized therapy,” said Katrin Pucknat, president, ResMed Germany. “Over 95% of patients in Germany suffering from sleep apnea are not diagnosed or treated. In addition, there are patients who have problems with their therapy and just stop it without considering an alternative. The partnership with Nyxoah will enable us to broaden the education around therapy options and empower patients to benefit from improved health outcomes.” 

Nyxoah and ResMed Germany will work to accelerate patient identification and better support patient set-up on the appropriate therapy through OSA helplines and direct-to-consumer marketing initiatives; sales and marketing efforts targeting ENTs and sleep physicians; and patient and clinician educational programs and symposiums. 

“We are thrilled to partner with ResMed Germany, as it strengthens further our patient-first approach to treating obstructive sleep apnea,” said Olivier Taelman, Nyxoah’s CEO. “OSA reduces quality of life and can result in other serious medical conditions, such as cardiovascular disease, and type 2 diabetes. Together, ResMed Germany and Nyxoah will heighten awareness of OSA and increase therapy penetration. The OSA ecosystem created by this partnership will guide patients from diagnosis to the right treatment for them, whether that is a mandibular device, continuous positive airway pressure (CPAP), or hypoglossal nerve stimulation (HGNS).” 


To comment on this post, please log in to your account or set up an account now.